COMBINATION CONTAINING PALBOCICLIB AND 6-(2,4-DICHLOROPHENYL)-5-[4-[(3S)-1-(3-FLUOROPROPYL)PYRROLIDINE-3-YL]-8,9-DIHYDRO-7H-BENZO[7]ANNULENE-2-CARBOXYLIC ACID AND APPLICATION THEREOF FOR TREATING CANCER Russian patent published in 2022 - IPC A61K31/40 A61K31/519 A61P35/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to the field of medicine, namely, to a combination for 4 breast cancer, containing 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidine-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid or a pharmaceutically acceptable salt thereof and palbociclib, as well as to a pharmaceutical composition for treating breast cancer, containing 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidine-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid or a pharmaceutically acceptable salt thereof and palbociclib and at least one pharmaceutically acceptable excipient, also applies to an application of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidine-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid or a pharmaceutically acceptable salt thereof, implemented by joint introduction with palbociclib for treating breast cancer, and to an application of palbociclib implemented by joint introduction with 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidine-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid or a pharmaceutically acceptable salt thereof for treating breast cancer, and also relates to a pharmaceutical kit for treating breast cancer, containing: (i) a first pharmaceutical composition containing 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidine-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient; (ii) a second pharmaceutical composition containing palbociclib and at least one pharmaceutically acceptable excipient; wherein both pharmaceutical compositions (i) and (ii) are placed in separate chambers and are intended for independent introduction, wherein each introduction in relation to the other one is simultaneous, separate, or distributed in time.

EFFECT: group of inventions ensures development of a combination of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidine-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid with palbociclib, well-tolerated, exhibiting high anti-tumour effectiveness, and causing regression of the tumour with synergistic effect compared with each active ingredient individually.

10 cl, 3 tbl, 2 ex, 3 dwg